Public Employees Retirement System of Ohio Has $126,000 Stock Position in Alkermes plc $ALKS

Public Employees Retirement System of Ohio increased its stake in Alkermes plc (NASDAQ:ALKS) by 480.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,418 shares of the company’s stock after buying an additional 3,657 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Alkermes were worth $126,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC raised its stake in Alkermes by 60.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,107 shares of the company’s stock valued at $463,000 after acquiring an additional 6,073 shares during the period. GAMMA Investing LLC increased its position in Alkermes by 4,255.3% during the 1st quarter. GAMMA Investing LLC now owns 178,176 shares of the company’s stock worth $5,396,000 after buying an additional 174,085 shares during the period. Wedge Capital Management L L P NC increased its position in shares of Alkermes by 5.0% in the first quarter. Wedge Capital Management L L P NC now owns 117,516 shares of the company’s stock worth $3,880,000 after purchasing an additional 5,607 shares during the period. Pallas Capital Advisors LLC bought a new position in shares of Alkermes in the first quarter worth $204,000. Finally, Avanza Fonder AB bought a new position in shares of Alkermes in the first quarter worth $266,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Price Performance

Shares of NASDAQ ALKS opened at $30.95 on Wednesday. Alkermes plc has a one year low of $25.17 and a one year high of $36.45. The business’s fifty day moving average price is $28.39 and its 200-day moving average price is $29.22. The stock has a market capitalization of $5.11 billion, a PE ratio of 14.88, a P/E/G ratio of 1.74 and a beta of 0.54.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. Alkermes had a return on equity of 24.86% and a net margin of 23.15%.The firm had revenue of $390.66 million for the quarter, compared to analysts’ expectations of $343.20 million. During the same quarter in the prior year, the firm earned $1.16 EPS. The business’s revenue for the quarter was down 2.1% compared to the same quarter last year. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS. As a group, equities analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Needham & Company LLC set a $43.00 price objective on Alkermes in a research note on Tuesday, September 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Alkermes in a research note on Saturday, September 27th. Wells Fargo & Company raised Alkermes to a “strong-buy” rating in a research note on Wednesday, September 3rd. The Goldman Sachs Group initiated coverage on Alkermes in a research note on Tuesday, July 15th. They set a “buy” rating and a $43.00 price target on the stock. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $46.00 price objective on shares of Alkermes in a research note on Tuesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Alkermes currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.